P4A experts regularly share their unique perspectives that inform and challenge the norm through articles and white papers.
The Cancer Drugs Fund (CDF) is expected to save the U.K. National Health Service (NHS) a minimum of £140 million over the next five years. Medicines that are recommended to the CDF by NICE (National Institute of Health and Care Excellence) have their prices negotiated lower than the manufacturer’s initial listed price. Over 15,000 patients […]Read More
February 4 was World Cancer Day and here at Partners4Access, we are having a look back at how cancer treatments have evolved through the years and where they are likely to go in the future. First came surgery In the 18th century, surgery was hailed as the first effective cancer treatment. The discovery of anesthesia […]Read More
For the rapidly developing orphan drug market, change is a constant. From new technologies to discussions over pricing, the estimated $137 billion market will witness new challenges for biopharma companies in the rare disease space. In a bid to unravel these barriers and with 11 months more to go in 2018, the team at Partners4Access […]Read More
Roche’s new haemophilia treatment, Hemlibra, is has a high estimated price tag of $482,000 for the first year of treatment and $448,000 for every subsequent year. Despite this, an analysis by the U.S. Institute for Clinical and Economic Review (ICER) has revealed that the treatment is still cost effective. The report stated that the Hemlibra […]Read More
From 1 March 2000 to 31 December 2017, NICE (National Institute for Health and Care Excellence) published over 800 healthcare technology recommendations. In total, 81% of those decisions were recommended, optimized or recommended for use in the Cancer Drugs Fund (CDF). Why then is NICE considered such a tough cookie when it comes to […]Read More
French pharmaceutical giant Sanofi have agreed to acquire Bioverativ, a U.S. hemophilia specialist for $11.6 billion. This deal is the biggest for Sanofi in seven years, with the aim of achieving a stronger position in the rare disease space. After initially falling due to investor speculation that Bioverativ was overvalued, shares in Sanofi have since […]Read More
Orphan Drug Pricing: Is Eurordis call to reduce prices by 3-5 times the answer to unequitable access?
Partners4Access comments on the new Eurordis Position Paper Earlier this month Eurordis published its position paper on orphan drug access. Whilst the report is commendable in pushing to drive equitable access for patients; their call to reduce orphan drug prices by 3 to 5 times by 2025 is no guarantee of full patient access. Affordability […]Read More
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) announced that there would be no sudden changes to the UK regulatory framework in the event of a no-deal following Brexit negotiations. It went on to confirm that it would provide “adequate notice to industry and ensure that companies had sufficient time to implement any changed […]Read More
The biotech venture capital firm Atlas Ventures has announced the creation of Generation Bio, a company that has developed a system by which the dosage of a gene therapy can be varied to maximise the potential benefit. The company has started on the back of a $25 million Series A funding round from Atlas. The […]Read More
Spark Therapeutics has announced its recently approved Luxturna (voretigene neparvovec-rzyl), a gene therapy treatment for biallelic RPE65 mutation-associated retinal dystrophy will cost $425 000 per eye, or $850 000 in total, in the U.S. This is below the $1 million price tag that was originally speculated. Spark Therapeutics is also working with Harvard Pilgrim, a […]Read More